GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29346-29358

  Zhang, Xinmin ^a   Meng, Shulin ^a   Zhang, Rong ^a   Ma, Buyun ^a,f   Liu, Tao ^b,e   Yang, Yu ^c   Xie, Wenjie ^a   Liu, Xianglei ^a   Huang, Fang ^d   Zhou, Xiumei ^a   Liu, Xinyuan ^a,b   Wang, Yigang ^a  

^a ZHEJIANG SCI TECH UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^c CENTRAL CHINA NORMAL UNIVERSITY   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

GP73; Liver cancer stem like cells; Oncolytic adenovirus

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN 73; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS GD55; ONCOLYTIC ADENOVIRUS ZD55; UNCLASSIFIED DRUG; GOLM1 PROTEIN, HUMAN; MEMBRANE PROTEIN; ONCOLYTIC VIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CANCER TISSUE; CARCINOGENICITY; CELL DIFFERENTIATION; CELL KILLING; CELL QUIESCENCE; CELLULAR PARAMETERS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; STEM CELL SELF-RENEWAL; SUSPENSION CELL CULTURE; TUMOR XENOGRAFT; ADENOVIRIDAE; ANIMAL; DRUG SCREENING; GENE VECTOR; LIVER TUMOR; NONOBESE DIABETIC MOUSE; ONCOLYTIC VIROTHERAPY; PROCEDURES; SCID MOUSE; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84969802001     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8830     Document Type: Article

References (42)

1. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell. 2012; 21:283-296.
2. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell stem cell. 2012; 10:717-728.
3. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013; 501:328-337.
4. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest. 2013; 123:1911-1918.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
6. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, Zhang BX. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology. 2008; 52:224-232.
7. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov. 2014; 13:497-512.
8. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012; 30:658-670.
9. Guo ZS, Bartlett DL. Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther. 2014; 21:261-263.
10. Cripe TP, Wang PY, Marcato P, Mahller YY, Lee PW. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther. 2009; 17:1677-1682.
11. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5:275-284.
12. Yang Y, Xu H, Shen J, Yang Y, Wu S, Xiao J, Xu Y, Liu XY, Chu L. RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancerinitiating cells. Cell Death & Dis. 2015; 6:e1760.
13. Yang Y, Xu H, Huang W, Ding M, Xiao J, Yang D, Li H, Liu XY, Chu L. Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus. J Cell Mol Med. 2015; 19:915-923.
14. Liu XY, Gu JF, Shi WF. Targeting gene-virotherapy for cancer. Acta Biochim Biophys Sin. 2005; 37:581-587.
15. Liu XY, Gu JF. Targeting gene-virotherapy of cancer. Cell research. 2006; 16:740.
16. Zhang ZL, Zou WG, Luo CX, Li BH, Wang JH, Sun LY, Qian QJ, Liu XY. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res. 2003; 13:481-489.
17. Wang Y, Liu T, Huang P, Zhao H, Zhang R, Ma B, Chen K, Huang F, Zhou X, Cui C, Liu X. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma. Oncotarget. 2015; 6:13564-13578. doi: 10.18632/oncotarget.3769.
18. Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012; 12:17.
19. Collura A, Marisa L, Trojan D, Buhard O, Lagrange A, Saget A, Bombled M, Mechighel P, Ayadi M, Muleris M, de Reynies A, Svrcek M, Flejou JF, et al. Extensive characterization of sphere models established from colorectal cancer cell lines. Cell Mol Life Sci. 2013; 70:729-742.
20. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63:5821-5828.
21. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, Wicha MS. In vitro propagation and transcriptional profiling of human mammary stem/ progenitor cells. Gene Dev. 2003; 17:1253-1270.
22. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, Levadoux-Martin M, Lee JB, Giacomelli AO, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell. 2012; 149:1284-1297.
23. Cao L, Zhou Y, Zhai B, Liao J, Xu W, Zhang R, Li J, Zhang Y, Chen L, Qian H, Wu M, Yin Z. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines. BMC Gastroenterol. 2011; 11:71.
24. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, Xu Y, Ma Q, Yang Z, Zhang Q, Ma L, Liu J, Xu S, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 2012; 56:1004-1014.
25. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151:56-67.
26. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011; 9:50-63.
27. Yin X, Li YW, Zhang BH, Ren ZG, Qiu SJ, Yi Y, Fan J. Coexpression of stemness factors Oct4 and Nanog predict liver resection. Annals of surgical oncology. 2012; 19:2877-2887.
28. Huang P, Qiu J, Li B, Hong J, Lu C, Wang L, Wang J, Hu Y, Jia W, Yuan Y. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clinical biochemistry. 2011; 44:582-589.
29. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semi Oncol. 2012; 39:461-472.
30. Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu T, Huang Y, Fang X, Lin S, Feng Q, Huang Z, Yang T, Luo Q, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis. 2014; 35:537-545.
31. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133:704-715.
32. Fischer KR, Durrans A, Lee S, Sheng J, Li F, Wong ST, Choi H, El Rayes T, Ryu S, Troeger J, Schwabe RF, Vahdat LT, Altorki NK, et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. 2015.
33. Chen K, Man K, Metselaar HJ, Janssen HL, Peppelenbosch MP, Pan Q. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transpl. 2014; 20:261-9.
34. Lu Y, Zhang TF, Shi Y, Zhou HW, Chen Q, Wei BY, Wang X, Yang TX, Chinn YE, Kang J, Fu CY. PFR peptide, one of the antimicrobial peptides identified from the derivatives of lactoferrin, induces necrosis in leukemia cells.Sci Rep. 2016; 6:20823. doi: 10.1038/srep20823.
35. Thaci B, Ulasov IV, Ahmed AU, Ferguson SD, Han Y, Lesniak MS. Anti-angiogenic therapy increases intratumoral adenovirus distribution by inducing collagen degradation. Gene Ther. 2013; 20:318-327.
36. Liu XY. The Excellent Anti-Tumour Strategy (CTGVT, OV-gene) and the Excellent Anti-Tumor Gene (IL-24). International journal of biomedical science. 2012; 8:87-93.
37. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, Stephan C, Jung K, Pilarsky C, Dietel M, Moch H. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Brit J Cancer. 2008; 99:939-948.
38. Chen LG, Wang HJ, Yao HB, Guan TP, Wu F, He XJ, Ma YY, Tao HQ, Ye ZY. GP73 is down-regulated in gastric cancer and associated with tumor differentiation. World J Surg Oncol. 2013; 11:132.
39. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D'Alessio AC, Young RA, Weinberg RA. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell. 2013; 154:61-74.
40. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A. 2011; 108:7950-7955.
41. Tata PR, Mou H, Pardo-Saganta A, Zhao R, Prabhu M, Law BM, Vinarsky V, Cho JL, Breton S, Sahay A, Medoff BD, Rajagopal J. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature. 2013; 503:218-223.
42. Stange DE, Koo BK, Huch M, Sibbel G, Basak O, Lyubimova A, Kujala P, Bartfeld S, Koster J, Geahlen JH, Peters PJ, van Es JH, van de Wetering M, et al. Differentiated Troy + chief cells act as reserve stem cells to generate all lineages of the stomach epithelium. Cell. 2013; 155:357-368.